ReviewInternational journal of molecular sciences2022
Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Antigenic Variation and Immune Recognition Inference From the COVID-19 Pandemic: An In Silico Comparative Analysis of Spike T Cell Epitopes From the SARS-CoV-2 Variants of Concern.Influenza and other respiratory viruses · 2026Article
- Structural and Conformational Impact of Deleterious Spike Protein Mutations in SARS-CoV-2 Omicron Lineages.bioRxiv : the preprint server for biology · 2025Article
- Risk factors for relapse and aggravation in membranous nephropathy after COVID-19 infection.BMC nephrology · 2025Article
- Early symptoms and 12-week follow-up of pediatric omicron infections during the Beijing outbreak.Frontiers in pediatrics · 2025Article
- Long-term symptoms after SARS-CoV-2 infection in a cohort of people living with HIV.Infection · 2024Observational
- Clinical Evaluation of Direct Reverse Transcription PCR for Detection of SARS-CoV-2 Compared to Conventional RT-PCR in Patients with Positive Rapid Antigen Test Results during Circulation of Emerging Viral Variants.Diagnostics (Basel, Switzerland) · 2023Article
- Detection of SARS-CoV-2 RNA in exhaled breath and its potential for prevention measures.Infection prevention in practice · 2023Article
- The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution.Heliyon · 2023Article
- Article
- SARS-CoV-2 Omicron variant causes brain infection with lymphoid depletion in a mouse COVID-19 model.Laboratory animal research · 2023Article
- Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants.Frontiers in plant science · 2023Article
- Article
- Distinguishing COVID-19 from seasonal influenza in patients under age 65 years-a retrospective observational cohort study comparing the 2009 influenza A (H1N1) and 2022 SARS-CoV-2 pandemics.Frontiers in cellular and infection microbiology · 2023Observational
- Direct Nasal Swab for Rapid Test and Saliva as an Alternative Biological Sample for RT-PCR in COVID-19 Diagnosis.Microbiology spectrum · 2022Article
- Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination.Vaccines · 2022Article
- Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study.Emerging microbes & infections · 2022Observational
- Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review.Medicina (Kaunas, Lithuania) · 2022Review
- Article
- Association Between Weather Parameters and SARS-CoV-2 Confirmed Cases in Two South African Cities.GeoHealth · 2022Article
- Performance of nasopharyngeal swab and saliva in detecting Delta and Omicron SARS-CoV-2 variants.Journal of medical virology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Coronavirus disease 2019 (COVID-19) pandemic poses a great threat to global public health. The original wild-type strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has genetically evolved, and several variants of concern (VOC) have emerged. On 26 November 2021, a new variant named Omicron (B.1.1.529) was designated as the fifth VOC, revealing that SARS-CoV-2 has the potential to go beyond the available therapies. The high number of mutations harboured on the spike protein make Omicron highly transmissible, less responsive to several of the currently used drugs, as well as potentially able to escape immune protection elicited by both vaccines and previous infection. We reviewed the latest publication and the most recent available literature on the Omicron variant, enlightening both reasons for concern and high hopes for new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.